OGIYX
Price
$59.24
Change
+$0.56 (+0.95%)
Updated
Jun 18 closing price
Net Assets
2.31B
RSLEX
Price
$84.13
Change
+$1.28 (+1.54%)
Updated
Jun 18 closing price
Net Assets
91.47B
Interact to see
Advertisement

OGIYX vs RSLEX

OGIYX vs RSLEX Comparison Chart in %
View a ticker or compare two or three
VS
OGIYX vs. RSLEX commentary
Jun 22, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OGIYX is a Buy and RSLEX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RSLEX has more cash in the bank: 91.5B vs. OGIYX (2.31B). RSLEX pays higher dividends than OGIYX: RSLEX (0.65) vs OGIYX (0.32). OGIYX was incepted earlier than RSLEX: OGIYX (25 years) vs RSLEX (24 years). RSLEX (1.00) is less costly to investors than OGIYX (0.90). OGIYX is a more actively managed with annual turnover of: 136.00 vs. RSLEX (41.00). RSLEX has a lower initial minimum investment than OGIYX: RSLEX (250) vs OGIYX (1000). RSLEX annual gain was more profitable for investors over the last year : 22.39 vs. OGIYX (18.55). RSLEX return over 5 years is better than : 0.03 vs. OGIYX (-27.17).
OGIYXRSLEXOGIYX / RSLEX
Total Expense Ratio0.901.0090%
Annual Report Gross Expense Ratio0.901.0090%
Fund Existence25 years24 years-
Gain YTD14.14315.86689%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets2.31B91.5B3%
Annual Yield % from dividends0.320.6549%
Returns for 1 year18.5522.3983%
Returns for 3 years12.4536.1734%
Returns for 5 years-27.170.03-83,742%
Returns for 10 years30.6896.7332%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBFAX21.630.69
+3.30%
VanEck Emerging Markets A
ABEMX22.460.61
+2.79%
abrdn Emerging Markets Instl
POMIX78.870.89
+1.14%
T. Rowe Price Total Equity Market Idx
SSEYX678.697.28
+1.08%
State Street Equity 500 Index II
CAXCX20.620.06
+0.29%
Catalyst/MAP Global Equity C